Spire Healthcare Group (LON:SPI) Stock Price Down 17.8% Following Analyst Downgrade

Spire Healthcare Group plc (LON:SPI) was down 17.8% during mid-day trading on Thursday after Deutsche Bank Aktiengesellschaft lowered their price target on the stock from GBX 320 to GBX 300. Deutsche Bank Aktiengesellschaft currently has a buy rating on the stock. Spire Healthcare Group traded as low as GBX 169 ($2.18) and last traded at GBX 184.60 ($2.39). Approximately 5,565,048 shares traded hands during trading, an increase of 727% from the average daily volume of 672,747 shares. The stock had previously closed at GBX 224.50 ($2.90).

Spire Healthcare Group Stock Down 6.0 %

The firm has a market cap of £711.58 million, a price-to-earnings ratio of 25.22, a PEG ratio of 1.06 and a beta of 0.96. The company has a quick ratio of 0.74, a current ratio of 0.70 and a debt-to-equity ratio of 62.25. The firm has a fifty day moving average price of GBX 227.28 and a 200-day moving average price of GBX 229.74.

Spire Healthcare Group (LON:SPI) last announced its quarterly earnings results on Thursday, March 6th. The company reported GBX 8.80 ($0.11) earnings per share for the quarter. Spire Healthcare Group had a net margin of 1.96% and a return on equity of 3.82%. As a group, sell-side analysts forecast that Spire Healthcare Group plc will post 15.6634747 EPS for the current year.

Spire Healthcare Group Company Profile

Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.